




RealRate

PHARMACEUTICAL 2013

Avanir Pharmaceuticals INC
Rank 138 of 218



The relative strengths and weaknesses of Avanir Pharmaceuticals INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Avanir Pharmaceuticals INC compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 29% points. The greatest weakness of Avanir Pharmaceuticals INC is the variable Selling, General and Administrative Expense, reducing the Economic Capital Ratio by 54% points.

The company's Economic Capital Ratio, given in the ranking table, is 170%, being 50% points below the market average of 220%.

Input Variable	Value in 1000 USD
Assets, Current	80,915
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	20,318
Liabilities, Non-Current	0
Other Assets	3,289
Other Compr. Net Income	0
Other Expenses	3,509
Other Liabilities	28,856
Other Net Income	4,247
Other Revenues	37,075
Property and Equipment	1,809
Research and Development	23,066
Selling, General and Administrative Expense	74,491

Output Variable	Value in 1000 USD
Assets	86,012
Liabilities	49,175
Expenses	101,066
Revenues	37,075
Stockholders Equity	36,837
Net Income	-59,744
Comprehensive Net Income	-59,744
BaseVar	138,787
ECR before Limited Liability	30%
Economic Capital Ratio	170%